Long-Term Safety for Lumateperone (ITI-007) in the Treatment of Schizophrenia

被引：0
|
作者：
Vanover, Kimberly [1 ]
Correll, Christoph [1 ]
Weingart, Michal [1 ]
Saillard, Jelena [1 ]
Hossain, Shawn [1 ]
Glass, Steven [1 ]
Kozauer, Susan [1 ]
Satlin, Andrew [1 ]
Davis, Robert [1 ]
机构：
[1] Intracellular Therapies Inc, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2018年 / 43卷
关键词：
Schizophrenia Novel Treatment; Long-Term Safety; Antipsychotic;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
T184
引用
收藏
页码：S328 / S329
页数：2
相关论文
共 50 条
  • [11] Efficacy and safety of lumateperone (ITI-007) in the treatment of depressive episodes associated with bipolar I and II disorders
    Durgam, S.
    Satlin, A.
    Vanover, K. E.
    Davis, R. E.
    Edwards, J. B.
    Kozauer, S. G.
    Huo, J.
    Mates, S.
    Calabrese, J. R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S253 - S254
  • [12] Cardiometabolic safety of lumateperone (ITI-007): post hoc analyses of short-term randomized trials and an open-label long-term study
    Satlin, A.
    Durgam, S.
    Vanover, K. E.
    Davis, R. E.
    Chen, R.
    Mates, S.
    Correll, C. U.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S265 - S266
  • [13] Lumateperone (ITI-007): A Novel Approach for the Treatment of Multiple Neuropsychiatric and Neurologic Diseases
    Mates, Sharon
    Vanover, Kimberly E.
    Taylor, Eve
    Saillard, Jelena
    Weingart, Michal
    Snyder, Gretchen
    Hendrick, Joseph P.
    Li, Peng
    Wennogle, Lawrence P.
    Davis, Robert E.
    NEUROTHERAPEUTICS, 2018, 15 (01) : 242 - 243
  • [14] Advancing the Clinical Development of ITI-007 for the Treatment of Schizophrenia - Safety and Tolerability Data
    Davis, Robert
    Glass, Steven
    Saillard, Jelena
    Weingart, Michal
    O'Gorman, Cedric
    Correll, Christoph
    Mates, Sharon
    Vanover, Kimberly
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S227 - S227
  • [15] ITI-007 for the Treatment of Schizophrenia: A Differentiating Response Profile
    Vanover, Kimberly E.
    Davis, Robert E.
    Mates, Sharon
    BIOLOGICAL PSYCHIATRY, 2014, 75 (09) : 325S - 325S
  • [16] Effect of Lumateperone (ITI-007) on Quality of Life and Functional Disability in the Treatment of Bipolar Depression
    Edwards, John
    Durgam, Suresh
    Kozauer, Susan
    Davis, Robert
    Mates, Sharon
    Jain, Rakesh
    McIntyre, Roger
    NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 244 - 245
  • [17] Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders
    Mazza, Marianna
    Marano, Giuseppe
    Traversi, Gianandrea
    Sani, Gabriele
    Janiri, Luigi
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2020, 19 (04) : 243 - 247
  • [18] Lumateperone (ITI-007) in the Treatment of Bipolar Depression: Results From a Randomized Clinical Trial
    Durgam, Suresh
    Satlin, Andrew
    Vanover, Kimberly
    Davis, Robert
    Kozauer, Susan
    Chen, Richard
    Mates, Sharon
    Calabrese, Joseph
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 450 - 451
  • [19] Effect of Lumateperone (ITI-007) on Quality of Life and Functional Disability in the Treatment of Bipolar Depression
    Edwards, John B.
    Durgam, Suresh
    Kozauer, Susan G.
    Jain, Rakesh
    McIntyre, Roger S.
    CNS SPECTRUMS, 2023, 28 (02) : 238 - 238
  • [20] Favorable Clinical Safety Profile for Lumateperone (ITI-007) - Switching From Standard-Of-Care Antipsychotic Therapy in Patients With Schizophrenia
    Vanover, Kimberly
    O'Gorman, Cedric
    Glass, Steven
    Saillard, Jelena
    Weingart, Michal
    Mates, Sharon
    Correll, Christoph
    Davis, Robert
    NEUROPSYCHOPHARMACOLOGY, 2017, 42 : S416 - S417
12345